Real-world approaches for extending progression-free survival in patients with metastatic pancreatic neuroendocrine tumors: focus on timing, sequencing, regimen initiation, and maintenance strategies using somatostatin analogs, targeted agents, and peptide receptor radiotherapy.

Wolin, Edward M

Wolin, Edward M.

Affiliation

Wolin EM; Center for Carcinoid and Neuroendocrine Tumors, Mount Sinai School of Medicine, New York, New York.

Clin Adv Hematol Oncol ; 16 Suppl 17(9): 11-14, 2018 Sep.

Article in En | MEDLINE | ID: mdl-30807563

Subject(s)

Antineoplastic Agents/therapeutic use; Hormones/therapeutic use; Molecular Targeted Therapy/methods; Neoplasm Metastasis/drug therapy; Neoplasm Metastasis/radiotherapy; Pancreatic Neoplasms/drug therapy; Pancreatic Neoplasms/radiotherapy; Somatostatin/therapeutic use; Hormones/chemistry; Humans; Neoplasm Metastasis/pathology; Neovascularization, Pathologic/drug therapy; Neovascularization, Pathologic/pathology; Neovascularization, Pathologic/radiotherapy; Pancreatic Neoplasms/metabolism; Pancreatic Neoplasms/pathology; Progression-Free Survival; Receptors, Somatostatin/metabolism; Signal Transduction/drug effects; Somatostatin/analogs & derivatives; TOR Serine-Threonine Kinases/metabolism

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Somatostatin / Molecular Targeted Therapy / Hormones / Neoplasm Metastasis / Antineoplastic Agents Limits: Humans Language: En Journal: Clin Adv Hematol Oncol Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2018 Document type: Article

Search on Google

Add to My VHL

XML

PubMed Links